Non-Small Cell Lung Cancer Treatment Market Trends

Growth Drivers

• Higher patient pool: Unhealthy lifestyle and growing pollutants in the environment are adversely impacting the lung condition of the population, leading to an increased number of cases of non-small cell lung cancer. Global data analysis shows that more than 80% of the global lung cancer cases are from Europe and Germany, with a gradual rise in diagnosis. Advancement within the healthcare quality accelerates the patient pool for speedy recovery from health risks. As per the study of the Agency for Healthcare Research and Quality, early diagnosis and intervention lead to recovery through therapeutic intervention. This ensured raised awareness within the market and achieved a growth in early diagnosis and elevated market demand for non-small cell lung cancer treatment.
• Innovation and clinical trials: Constant research and development directed the market toward innovation that ensured better patient outcomes. It is anticipated that innovations such as targeted therapy and advancements in immune oncology will lead to market expansion. Companies, including AstraZeneca, achieved clearance for Osimertinib that ensures first-in-class treatment for patients dealing with non-small cell lung cancer. The Food and Drug Administration (FDA) approval provided adequate guidance and legal alignment for the checkpoint factor inhibitors and targeted therapies. This helped to bring better efficiency within the treatment landscape and ensure better patient outcomes. For instance, clinical trials are performed at a higher rate in the Asia Pacific and North America for biomarker-based therapy to accelerate the market performance.
• Advancements in targeted therapy and immunotherapy: The arrival of targeted therapies and immune checkpoint inhibitors altered the treatment landscape for NSCLC. The success of these agents has even continued to expand subsequent labels, including first-line approval and combination therapies. Pharmaceutical companies continue investing heavily in R&D, which keeps new agents coming to market and makes the pipeline strong. Additionally, with more patients receiving biomarker testing, the addition of personalized treatments is increasing and continuing to accelerate our market growth.

Challenges

• Government control on the price cap and reimbursement issues: Maintaining a balance with the cost of production and the revenue accumulation for the business often faces barriers due to the government control on the price caps. Collaborating with the national health agencies led the companies to bear high losses due to the price control. According to the data published by the World Health Organization, budget constraints lead the low-income countries to exclude the expenses of the non-small cell lung cancer treatment from national formularies.  The high cost of the treatment created a high disparity in accessibility for patients due to limited reimbursement policies in the global platform.
• Drug resistance and limited durability of response: Although patients can see immediate benefits from targeted therapies or immunotherapy for long periods, they may eventually show resistance, and/or have disease progression. This is a limitation of long-term treatment effects that requires ongoing development of new agents and combination therapies. Additionally, a significant proportion of NSCLC is diagnosed at an advanced or metastatic state in which treatment options become limited and /or likely not effective. This will ultimately delay the opportunity for curative measures and lead to poor overall survival and complicated management plans.